Ignite Creation Date:
2024-05-05 @ 11:58 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01460134
Status:
COMPLETED
Last Update Posted:
2018-01-31
First Post:
2011-10-12
Brief Title:
A Study of CDX-1127 Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers
Sponsor:
Celldex Therapeutics
Organization:
Celldex Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Primary Lymphoma of the Central Nervous System |
| CD27 Expressing B-cell Malignancies for Example Hodgkins Lymphoma |
| Chronic Lymphocytic Leukemia |
| Mantle Cell Lymphoma |
| Marginal Zone B Cell Lymphoma |
| Any T-cell Malignancy |
| Solid Tumors Metastatic Melanoma Renal Clear Cell Carcinoma |
| Hormone-refractory Prostate Adenocarcinoma Ovarian Cancer |
| Colorectal Adenocarcinoma Non-small Cell Lung Cancer |
| Burketts Lymphoma |
Keywords:
| Name | View |
|---|---|
| non-small cell lung cancer | View |
| CD27 expressing Hematologic Malignancies | View |
| CD27 expressing Solid Tumors | View |
| chronic lymphocytic leukemia | View |
| Burketts lymphoma | View |
| mantle cell lymphoma | View |
| primary lymphoma of the central nervous system | View |
| marginal zone B cell lymphoma | View |
| solid tumor | View |
| metastatic melanoma | View |
| renal clear cell carcinoma | View |
| hormone-refractory prostate adenocarcinoma | View |
| ovarian cancer | View |
| colorectal adenocarcinoma | View |